Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Dunaújváros

12 clinical trials in Dunaújváros, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dunaújváros at a glance
12
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

12 trials in Dunaújváros

Open in trial search

A study testing xanomeline tartrate and trospium chloride for treating agitation in patients with Alzheimer's disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of trospium chloride and xanomeline tartrate combination for agitation in Alzheimer's disease patients: Long-term safety evaluation

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic skin-derived ABCB5-POSITIVE dermal mesenchymal stromal cells
  • Sponsor:Rheacell GmbH & Co. KG

Migraine

Not recruiting

Study on the Safety and Effectiveness of MEDI0618 for Reducing Migraine Days in Adults with Episodic Migraine

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MEDI0618
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Dunaújváros

What the registry says about research in the country

01 Cardiovascular and Stroke Research

Innovative trials focusing on atherosclerotic cardiovascular disease prevention and stroke treatment, evaluating new therapeutic approaches for reducing major cardiovascular events.

  • Primary ASCVD Prevention
  • Acute Ischemic Stroke
  • High-Risk TIA Management

Studies aim to demonstrate the effectiveness of novel compounds in preventing cardiovascular complications and improving stroke outcomes.

02 Renal and Metabolic Disorders

Research examining combination therapies for chronic kidney disease with concurrent hypertension, exploring innovative treatment approaches for better patient outcomes.

  • CKD Management
  • Hypertension Control
  • Primary Biliary Cholangitis

Trials focus on evaluating new medications to slow disease progression and improve quality of life.

03 Neurological and Pain Management

Studies investigating novel treatments for episodic migraine, focusing on preventive therapies to reduce headache frequency and severity.

  • Migraine Prevention
  • Headache Management

Research aims to develop effective preventive treatments for patients suffering from recurring migraines.

04 Gastrointestinal and Inflammatory Conditions

Clinical investigations of new therapies for ulcerative colitis, examining both short-term improvement and long-term maintenance treatments.

  • Inflammatory Bowel Disease
  • UC Management
  • Long-term Disease Control

Studies evaluate novel compounds for achieving endoscopic improvement and symptomatic remission.

05 Wound Healing and Regenerative Medicine

Innovative research utilizing stem cell therapy for treating chronic venous ulcers, focusing on wound healing in difficult-to-treat cases.

  • Chronic Wound Management
  • Regenerative Medicine
  • Venous Ulcer Treatment

Trials explore advanced therapeutic approaches for non-healing wounds using cellular treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.